跳至主要内容
临床试验/jRCT2080221233
jRCT2080221233未知1 期

Phase I Clinical Study of E7389 in Patients With Solid Tumors

Eisai Co., Ltd.0 个研究点目标入组 24 人开始时间: 待定

试验速览

阶段
1 期
入组人数
24
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Open-Label study

入排标准

年龄范围
20age old over 至 75age old under(—)
性别
All

入选标准

  • Patients with histologically or cytologically confirmed solid tumors.
  • Patients who have progressed on or following standard therapy and with no other treatment options.
  • Patients having a performance status (PS) of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

排除标准

  • Patients with systemic infection with a fever (38°C).
  • Patients with a large amount of pleural effusion, ascites and pericardial fluid requiring drainage.
  • Patients with brain metastasis with clinical symptoms.

结局指标

主要结局

-

Dose limiting toxicity (DLT) and maximum tolerated dose (MTD)

次要结局

未报告次要终点

研究者

相似试验